HPV16-positive Oropharyngeal cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Oropharyngeal squamous cell carcinoma (OPSCC) is a term used to describe a variety of cancers that can affect the tonsils, base of the tongue, soft palate, and uvula. Similar to other head and neck squamous cell carcinomas (HNSCCs), OPSCC has historically been linked to cigarette and alcohol use. In high-income countries, OPSCC incidence is among those that are rising the quickest of all cancer types. Both HPV+ and HPV- OPSCC incidence have increased over the past 20 years, though data indicates that the former is expanding more quickly. Between 2000 and 2017, there were three times as many HPV+ OPSCC cases in Denmark as there were HPV-related illnesses. Surgery, radiation therapy (RT), and chemotherapy are all options for treating oropharyngeal squamous cell carcinoma (OPSCC) that is related to HPV, either singly or in combination. With these treatment modalities, nonsmoking patients with early-stage HPV-associated OPSCC have a high chance of recovery. With the exception of clinical trials, treatment for patients with HPV associated OPSCC is the same as for those with HPV negative OPSCC.

Description

Oropharyngeal squamous cell carcinoma (OPSCC) is a term used to describe a variety of cancers that can affect the tonsils, base of the tongue, soft palate, and uvula. Similar to other head and neck squamous cell carcinomas (HNSCCs), OPSCC has historically been linked to cigarette and alcohol use. Human papillomavirus (HPV) infection is linked to the majority of newly discovered cases of oropharyngeal squamous cell carcinoma (OPSCC), portending a very good prognosis, especially for low-risk patients with non-bulky tumors and little smoking history. The incidence of OPSCC has increased over the past 20 years due to the carcinogenic human papillomavirus (HPV) infection, which has emerged as a key risk factor, whereas the frequency of HNSCC has decreased over that time in the majority of high-income nations. More specifically, HPV currently accounts for 51.8% and 71%, respectively, of all OPSCCs in the UK and the USA.

HPV16-positive Oropharyngeal cancer (Epidemiology)

In high-income countries, OPSCC incidence is among those that are rising the quickest of all cancer types. Both HPV+ and HPV- OPSCC incidence have increased over the past 20 years, though data indicates that the former is expanding more quickly. Between 2000 and 2017, there were three times as many HPV+ OPSCC cases in Denmark as there were HPV-related illnesses. Compared to HPV- HNSCC, tonsillar squamous cell carcinoma (SCC), a faster increase in HPV+ HNSCC has been observed in Taiwan. Between 2000 and 2006, the incidence of HPV+ OPSCCs in Italy increased from 16% to 7% of all OPSCCs, to 46% between 2013 and 2018. Southern Asia and sub-Saharan Africa are home to the majority of the world's cases of cervical cancer linked to HPV. However, there aren't many epidemiological studies that focus on HPV+ OPSCC, so it's not clear if there aren't any rising trends in these areas or if they've just been missed. The few reports that are currently available show that, despite high rates of HPV-associated cervical cancer, HPV+ OPSCCs are uncommon in sub-Saharan Africa. Men have historically developed HPV+ OPSCCs at a higher rate than women, despite the fact that this is still not fully understood. This might be caused by variations in sex-transmitted infection susceptibility and transmission rates. A birth cohort effect has caused the disease burden to begin shifting towards older men, contrary to prior research that suggested the incidence of HPV+ OPSCC decreased with age. White people in the USA have a higher incidence of HPV+ OPSCC than people of other racial or ethnic groups. An analysis of the Surveillance, Epidemiology and End Results (SEER) database revealed that, despite a decline in Black men's rates, oropharyngeal cancer rates have significantly increased in men of white or Hispanic ethnicity as well as in men of other ethnicities. However, a different study found that compared to White Americans, Black and Hispanic Americans have seen a noticeably faster increase in the incidence of HPV+ OPSCCs.

HPV16-positive Oropharyngeal cancer -Current Market Size & Forecast Trends

The market for HPV16-positive oropharyngeal cancer is expected to witness significant growth, with projections estimating a rise from approximately USD 710 million in 2020 to around USD 1.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of about 6.5%. This growth is driven by the increasing incidence of HPV-related oropharyngeal cancers, which now account for approximately 75% of all oropharyngeal cancers, with HPV16 being the predominant strain responsible for these cases. The rising awareness of HPV's role in cancer development, coupled with advancements in treatment options such as immunotherapy and targeted therapies, is enhancing patient outcomes and driving market demand. North America is expected to dominate the market due to its robust healthcare infrastructure and significant investments in cancer research, while regions with rising HPV vaccination rates may also see increased market activity as preventive measures become more effective. Overall, the HPV16-positive oropharyngeal cancer market is well-positioned for substantial growth through 2035, supported by ongoing innovations in therapeutic strategies and increased emphasis on early detection and prevention initiatives.

Surgery, radiation therapy (RT), and chemotherapy are all options for treating oropharyngeal squamous cell carcinoma (OPSCC) that is related to HPV, either singly or in combination. With these treatment modalities, nonsmoking patients with early-stage HPV-associated OPSCC have a high chance of recovery. With the exception of clinical trials, treatment for patients with HPV associated OPSCC is the same as for those with HPV negative OPSCC. There isn't enough phase III data to adjust therapy based on HPV status, despite the fact that testing for HPV association offers prognostic information. Given that these patients have excellent long-term prognoses, the treatment strategy must take into account oropharyngeal function preservation, the possibility of late treatment-related toxicities, and, if at all possible, avoid needless intensification of therapy. An important option for some patients with locoregional disease is improved surgical techniques, frequently utilizing transoral approaches. Based on pathologic characteristics, surgery might result in a reduction in the need for adjuvant radiation therapy (RT) or chemotherapy, though this strategy is still being researched in deintensification trials. A decrease in adjuvant therapy may be considered against potential surgical complications.

Report Highlights

HPV16-positive Oropharyngeal cancer - Current Market Trends

HPV16-positive Oropharyngeal cancer - Current & Forecasted Cases across the G8 Countries

HPV16-positive Oropharyngeal cancer - Market Opportunities and Sales Potential for Agents

HPV16-positive Oropharyngeal cancer - Patient-based Market Forecast to 2035

HPV16-positive Oropharyngeal cancer - Untapped Business Opportunities

HPV16-positive Oropharyngeal cancer - Product Positioning Vis-a-vis Competitors' Products

HPV16-positive Oropharyngeal cancer - KOLs Insight